Finward Bancorp Purchases New Holdings in Pfizer Inc. (NYSE:PFE)

Finward Bancorp bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 13,253 shares of the biopharmaceutical company's stock, valued at approximately $352,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter worth $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE stock traded up $0.09 on Friday, hitting $22.13. The company had a trading volume of 53,854,504 shares, compared to its average volume of 40,486,092. The firm has a market cap of $125.50 billion, a P/E ratio of 15.69, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a 50-day moving average price of $24.88 and a 200-day moving average price of $26.15. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group lowered their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.